Abu Dhabi closes eatery for violating food laws, posing 'significant risk to public health'
The authority took to Instagram today to inform residents that it has issued the decision. The eatery, located in Al Shahama, was found in violation of Law No. (2) of 2008 regarding food in the Emirate of Abu Dhabi and its associated legislation.
Tasif Restaurant, holding the trade licence number CN-2836859, was conducting practices that posed "a significant risk to public health".
Last week, the authority shut down Strong Tea Cafeteria in Mohamed Bin Zayed City, for violating food safety laws in the emirate.
The cafeteria was previously fined three times and issued a warning of administrative closure for the spread of pests and insects in the facility and the lack of cleanliness in it.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
3 days ago
- Gulf Today
Abu Dhabi shuts down Cocobona Cafeteria after repeated food safety violations
Abu Dhabi Agriculture and Food Safety Authority (ADAFSA) has issued an administrative closure order against "Cocobona Cafeteria" in Abu Dhabi, holding commercial licence (CN-3952783), for violating Law No (2) of 2008 concerning food in the Emirate of Abu Dhabi and its associated regulations. The closure was also due to the establishment's risk to public health. ADAFSA stated that the food control report indicated the administrative closure was a result of repeated food safety violations and the failure to implement effective corrective measures, necessitating immediate action to ensure food safety and consumer health. The authority emphasised that the closure order will remain in effect until the violations are rectified and that the establishment may resume work only after fully addressing all issues and complying with all food safety requirements. ADAFSA urged the public to report any violations observed in food establishments or suspicions regarding food products by calling the toll-free Abu Dhabi Government number 800555 so that inspectors take necessary actions to ensure safe and healthy food.
Gulf Today
13-07-2025
- Gulf Today
Patient awarded Dhs100,000 over medical error in Abu Dhabi after 20 per cent foot disability
The Court of Cassation in Abu Dhabi rejected an appeal against a ruling awarding a patient Dhs100,000 in compensation due to a non-gross medical error by the treating physician. The error resulted in the patient experiencing difficulty in walking due to a permanent disability of approximately 20% of the original functionality of the foot. The court clarified that the UAE legislator has been keen on balancing the need for doctors to have reassurance, confidence, and freedom in practising their profession, while also ensuring patients are protected from medical errors and have the right to compensation for resulting damages. The court referred to Article 18 of Decree-Law No. 4 of 2016 concerning Medical Liability, which stipulates that compensation claims arising from medical liability are only admissible after recourse to and review by Medical Liability Committees. Additionally, Article 19 of the same law mandates that all complaints related to medical errors be submitted or referred to the health authority, which has the right to refer complaints to the Medical Liability Committee, the court stated. The committee then must prepare a report on each case and submit it to the health authority within thirty days from the date of referral. According to case file, the Medical Liability Committee stated in its report that the healthcare provided by the doctor did not meet established medical standards and that he committed a non-gross medical error by failing to directly dealing with the case and delaying surgical intervention, resulting in difficulty in walking and a permanent disability of 20%. The court noted that the case files lacked evidence proving the patient was employed at the time of the surgery, especially since his age at that time exceeded the legally mandated retirement age. Additionally, medical reports confirmed that the patient arrived at the hospital in a wheelchair, indicating he was unable to walk before the surgery. The court explained that the appealed ruling awarded the appellant Dhs100,000 as compensation for material and moral damages, which it deemed sufficient. Consequently, the court rejected the appeal.
Arabian Post
05-07-2025
- Arabian Post
Parkinson's Study Revives Hopes of Neuronal Recovery
A targeted drug therapy has shown potential to reverse cellular damage in Parkinson's disease by regenerating critical brain structures and restoring neuron function, according to new findings from a leading neuroscience research team. Scientists at Stanford University have demonstrated that suppressing the hyperactivity of a specific enzyme, LRRK2, with a compound called MLi-2 can prompt substantial recovery of dopaminergic signalling in a genetically engineered mouse model of Parkinson's. The treatment not only halted further degeneration but appeared to reverse structural impairments in the affected brain cells, marking a significant shift in understanding how Parkinson's progression might be modified at a cellular level. Parkinson's, a neurodegenerative condition marked by tremors, rigidity, and impaired movement, is primarily caused by the death of dopamine-producing neurons in the brain's substantia nigra. For decades, treatments have largely focused on symptom management rather than tackling the root causes of cellular dysfunction. The Stanford findings now suggest that correcting underlying molecular defects could pave the way for regenerative strategies. ADVERTISEMENT The breakthrough centres on the LRRK2 enzyme, mutations in which are among the most common genetic causes of Parkinson's. Overactive LRRK2 has been linked to damage of cellular structures called primary cilia — antenna-like projections that play a vital role in neuron communication and survival. The research team found that neurons in the striatum of the brain — a key region involved in motor control — lacked these cilia in the Parkinson's model mice. Using the LRRK2-inhibiting compound MLi-2, the team observed a significant regeneration of these lost cilia after three months of treatment. Dopamine signals began to function normally again in many of the affected neurons. The mice showed molecular signs of cellular recovery, with restored receptor localisation and improved intercellular communication. Importantly, the drug was administered after symptoms had started to appear, indicating that early-stage intervention could potentially reverse some aspects of the disease. Further investigations revealed that the repaired cilia helped restore the sonic hedgehog signalling pathway, which is essential for neuron protection and maintenance. In Parkinson's, reduced Shh signalling due to cilia loss contributes to further deterioration of neurons. Restoring this pathway through cilia regrowth suggests a dual benefit: halting ongoing degeneration and triggering repair mechanisms. Although the research was conducted on genetically modified mice, the implications for human forms of Parkinson's could be significant. LRRK2 mutations account for a relatively small percentage of all Parkinson's cases, but the pathway affected by this mutation may play a broader role in other forms of the disease, including idiopathic Parkinson's with unknown genetic causes. The MLi-2 compound itself is a highly selective, brain-penetrant molecule designed to inhibit LRRK2 activity without causing off-target effects. Previous efforts to target LRRK2 were hindered by concerns over safety and unintended consequences in other organs where the enzyme is also active. However, the current study found no major toxic effects over the duration of the experiment, opening the door for cautious optimism about its translational potential. ADVERTISEMENT Neuroscientists have long been searching for ways to go beyond dopamine replacement therapies, which offer temporary relief but do not prevent neuron loss. Deep brain stimulation and other invasive procedures are used in advanced cases but are not curative. A pharmacological approach that addresses root biological causes has remained elusive. The discovery that cellular antennae can regrow and restore critical signalling functions represents a conceptual leap in the field. Experts have noted that early intervention will be key. While the drug showed promise after symptoms appeared, the degree of neuronal recovery is likely to depend on how much degeneration has already taken place. Identifying Parkinson's earlier in its course, perhaps through biomarker detection, may significantly enhance the efficacy of such treatments. Further preclinical studies and safety evaluations are expected before MLi-2 or similar compounds move into human trials. Nonetheless, the research has sparked considerable interest among those exploring disease-modifying treatments. If replicated and expanded, the findings could contribute to a paradigm shift in the management of neurodegenerative conditions more broadly. The concept of regrowing cilia to restore function in damaged neurons could also have implications for other central nervous system disorders involving disrupted cell signalling. Beyond Parkinson's, researchers are already examining cilia dysfunction in conditions such as Alzheimer's and Huntington's disease.
